Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
スポンサーリンク
概要
- 論文の詳細を見る
(2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-l-azabicyclo[3.2.0]-heptane-2-carboxylic acid 4,4-dioxide (YTR-830H) is a new β-lactamase inhibitor. The degradation of this β-lactamase inhibitor in several buffer solutions, NaOH aqueous solution and NaOH-saturated methanol solution was investigated. In the initial step of degradation in aqueous solutions, YTR-830H was degraded to 2-amino-3-methyl-3-sulfino-4-(1H-1,2,3-triazol-1-yl)-butyric acid (YTR-830H-II) and formylacetic acid (YTR-830H-III) through (E)-5-methyl-5-sulfino-6-(1H-1,2,3-triazol-1-yl)-3-aza-1-heptene-1,4-dicarboxylic acid (YTR-830H-I) as an intermediate. The YTR-830H-II in all solutions then proceeded to an unidentified product, YTR-830H-IIa. In acidic solution it was converted to 1,2,3-triazole and several unidentified produts (YTR-830H-IIa, -IIb, -IIc and -IId). Degradation at various pHs showed different patterns and rates. Following degradation in NaOH-saturated methanol solution, 1-methyl hydrogen (E)- and (Z)-5-methyl-5-sulfino-6-(1H-1,2,3-triazol-1-yl)-3-aza-1-heptene-1,4-dicarboxylic acid (YTR-830H-Ia and -Ib) were detected.
- 社団法人日本薬学会の論文
- 1988-11-25
著者
-
吉田 健一郎
Tokushima Institute Taiho Pharmaceutical Co. Ltd.
-
東 龍太郎
大鵬薬品代謝分析研
-
南 慶典
Tokushima Institute, Taiho Pharmaceutical Co., Ltd.,
-
松島 英司
Biological Research Laboratory, Taiho Pharmaceutical Co., Ltd.,
-
南 慶典
Biological Research Laboratory, Taiho Pharmaceutical Co., Ltd.,
-
東 龍太郎
Biological Research Laboratory, Taiho Pharmaceutical Co., Ltd.,
-
吉田 健一郎
Biological Research Laboratory, Taiho Pharmaceutical Co., Ltd.,
-
丸中 照義
Biological Research Laboratory, Taiho Pharmaceutical Co., Ltd.,
-
南 慶典
Tokushima Institute Taiho Pharmaceutical Co. Ltd.
-
松島 英司
大鵬薬品代謝分析研
-
丸中 照義
Biological Research Laboratory Taiho Pharmaceutical Co. Ltd.
関連論文
- 33 新規抗腫瘍性抗生物質C-1027のクロモフォアの構造(口頭発表の部)
- Antitumor Agents. II : Regio- and Stereospecific Syntheses of 1-β-Alkyl-1-desoxypodophyllotoxin Derivatives and Biological Activity
- Alkaline and Neutral Degradation of Cefodizime (THR-221) and Structural Elucidation of the Products. II.
- Acidic Degradation of Cefodizime (THR-221) and Structural Elucidation of the Products. I
- Degradation of β-Lactamase Inhibitor (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H) in the Solid State : Structural Elucidation
- Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
- Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
- Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
- 新規抗悪性腫瘍薬 S-1 の各配合成分の体内動態 (第8報) : 動物種差および用量依存性
- 新規抗悪性腫瘍薬 S-1 の各配合成分の体内動態 (第6報) : ラットにおける S-1 の各配合成分の代謝
- S-1 のイヌにおける体内動態 - 線形性の検討 -
- 36 中国産Rabdosia属植物R.phyllostachys,R.rubescensならびにR.sculponeataの新ジテルペンの構造
- The Structure of Rubescensin C : A New Minor Diterpenoid isolated from Rabdosia rubescens
- Identification of Metabolites of 1-(Tetrahydro-2-furanyl)-5-fluorouracil (FT-207) formed in Vitro by Rat Liver Microsomes
- 門脈 - 体循環血濃度差法によるイヌ小腸及び肝の初回通過効果
- Tannins and Related Compounds. LXXXV. : Structures of Novel C-Glycosidic Ellagitannins, Grandinin and Pterocarinins A and B
- クリアランスモデルに基づいた TAS-102 経口投与時の FTD 体内動態の予測 : ラット, サルからヒトへ
- TAS-102経口投与におけるヒトFTD代謝の予測
- Gas Chromatographic-Mass Fragmentographic Determination of 5-Fluorouracil as a Metabolite of New 5-Fluorouracil Derivatives